The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment

https://doi.org/10.1016/j.ghir.2015.05.002Get rights and content

Highlights

  • HCC is a condition characterized by IGF-II overproduction

  • We therefore measured intact and pro-IGF-II in serum and well as IGF bioactivity in patients with HCC before and after treatment

  • HCC patients were compared with patients with liver cirrhosis patients and healthy controls

  • Our study showed that liver status has paramount effect on the circulating IGF-system, whereas the impact of HCC in much less

  • Thus, our data question the use of IGF-II as a marker of HCC.

Abstract

Background

Previous studies have demonstrated an elevated IGF-II mRNA expression and protein levels in tumors and blood from patients with hepatocellular carcinoma (HCC), hereby suggesting a role of IGF-II as a pathogenic marker of HCC. We hypothesized that in HCC, an increased IGF-II secretion would translate into an elevated circulating IGF bioactivity, which would normalize following treatment.

Methods

Patients with HCC (n = 39) were studied before and after radio-frequency ablation and/or transarterial chemo-embolization. Baseline data were compared to healthy subjects (n = 150) and patients with liver cirrhosis (n = 41). Serum levels of IGF ligands and IGF binding proteins (IGFBPs) were determined using gold standard methods as well as novel assays and compared to liver function tests and HCC treatment status.

Results

At baseline, HCC patients differed from cirrhosis patients and healthy controls regarding IGF-I (29 [23–37] vs. 12 [7–19] vs. 109 [103–116] μg/l), IGF-II (254 [224–288] vs. 118 [102–137] vs. 545 [525–566] μg/l) and IGF bioactivity (0.53 [0.41–0.68] vs. 0.29 [0.24–0.34] vs. 1.43 [1.33–1.53] μg/l) (mean [95% confidence interval], all age-adjusted P < 0.001). All variables but IGFBP-2 were strongly associated with liver status (MELD score), and accordingly, differences were either attenuated or disappeared when adjusted for MELD score. There was no effect of treatment on any IGF variables.

Conclusions

The marked differences in IGF and IGFBP levels between patients with HCC, liver cirrhosis and healthy subjects are mainly explained by variations in liver status. Therefore, this study questions the clinical utility of circulating IGF variables as markers of HCC.

Introduction

Hepatocellular carcinoma (HCC) is a common disease on a global scale and associated with chronic viral hepatitis, exposure to dietary aflatoxin B1, and liver cirrhosis [1]. Irrespective of etiology, the common trait in HCC consists of an imbalance between pro-apoptotic and anti-apoptotic signaling. Anti-apoptotic signaling in hepatocytes is maintained through the PI3-K/Akt and Ras/Raf/MEK/MAPK pathways [2], two major downstream targets of the IGF-I receptor (IGF-IR) [3]. As both IGF-I and IGF-II activate the IGF-IR, both growth factors may influence hepatocyte survival and enrich hepatocellular cancer stem cell populations [4].

The physiology, pathophysiology, and clinical utility of IGF-II have recently been reviewed [5]. Excess IGF-II stimulates cancer cell proliferation and increases cancer cell survival both in vitro and in vivo [6], including in HCC cells [7]. IGF-II is essential for intrauterine growth and placental development. Within the first weeks after birth, there is a shift from potent fetal promoters to a weaker adult promoter, resulting in a very low expression of the igf2 gene in the normal adult liver [8]. By contrast, an elevated igf2 gene expression has been demonstrated in neoplastic tissues from patients with HCC and in animal models of HCC [8], and this over-expression is linked to reactivation of the fetal promoters and deactivation of the adult promoter [9]. Indeed, reducing IGF-II mRNA levels with anti-sense oligonucleotides resulted in decreased cell proliferation in human hepatoma cell lines with high IGF-II secretion [10]. At the molecular level hepatitis B virus (HBV) and hepatitis C virus (HCV) increase the production of IGF-II, thus promoting growth and viability of malignant cells [8].

Several clinical studies have demonstrated elevated IGF-II levels (mRNA and protein) in both tumors and blood from HCC patients, hereby suggesting a role of IGF-II as a marker of HCC [11], [12], [13], [14], [15]. By contrast, others have found sparse evidence of an association between IGF-II and HCC [16]. The reasons for this discrepancy have not been thoroughly investigated. Furthermore, it remains to be clarified whether serum IGF-II may be used as a biomarker of the response to HCC treatment.

We hypothesized that IGF-II would be elevated in HCC and normalize with radio-frequency ablation (RFA) or transarterial chemo-embolization (TACE). IGF-II exerts its biological effects via interaction with the IGF-IR [3], and accordingly, we found it of interest to investigate the ability of serum from HCC patients to activate the IGF-IR under physiological conditions. To this end, an IGF-IR kinase receptor activation (KIRA) assay, developed and validated in our laboratory [17], was applied to compare serum obtained from well-characterized patients with HCC, patients with liver cirrhosis and healthy control subjects. This measure of IGF bioactivity was compared with measurements of IGF-I, IGF-II, and pro-IGF-II, using size exclusion gel chromatography at low pH, which is the gold standard method to eliminate IGFBP interference [18]. Finally, we assessed the impact of the marked reduction in tumor burden following RFA and TACE of HCC tumors on the circulating IGF system.

Section snippets

Patient Characteristics

The HCC patients included in this study were referred to the Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark, from December 2007 through October 2010. The Department is a tertiary treatment center for the Western part of Denmark with a population of 2 million inhabitants. Patients were diagnosed, staged and allocated to treatment according to international guidelines for management of HCC [19], [20] independently of study participation. This study focused on

IGF Values in HCC Patients are Markedly Different From Those of LC Patients and Healthy Controls

The baseline comparison showed marked differences in IGF-related measures (Table 2). The HCC patients had twice as high levels of bioactive IGF compared to LC patients, but for both groups levels were markedly below those observed in healthy controls (P < 0.001). Similar patterns were observed for IGF-I, IGF-II, and IGFBP-3, whereas pro-IGF-II and the IGF-I to IGFBP-3 ratio showed less pronounced but nevertheless significant differences (Table 2). IGFBP-2 was 10-fold elevated in LC patients and

Discussion

We have investigated the IGF system in HCC patients, using state of the art IGF-assays. As a novel finding, we report that tumor ablation does not affect serum IGF-II or IGF bioactivity. Furthermore, we demonstrate a strong influence of liver status on IGF variables, which may impact the interpretation of the existing literature on IGF variables in HCC patients.

In this study, patients with HCC showed serum IGF-II levels ranging between healthy controls and LC patients. Furthermore, serum IGF-II

Declaration of Interest

The authors declare no conflicts of interest.

Funding

This study was supported by grants from the Danish Cancer Society (DP08022) and from the Department of Clinical Medicine, Aarhus University. Henning Grønbæk is supported by a clinical research grant from the NOVO Nordisk Foundation.

References (41)

  • J.G. Scharf et al.

    Characterization of the insulin-like growth factor axis in a human hepatoma cell line

    Carcinogenesis

    (1998)
  • J.G. Scharf et al.

    The role of the IGF axis in hepatocarcinogenesis

    Horm. Metab. Res.

    (2003)
  • K. Breuhahn et al.

    Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma

    World J. Gastroenterol.

    (2008)
  • S.B. Lin et al.

    Antisense oligodeoxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II

    J. Biochem.

    (1997)
  • Z.Z. Dong et al.

    Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma

    World J. Gastroenterol.

    (2005)
  • H.M. El Tayebi et al.

    Expression of insulin-like growth factor-II, matrix metalloproteinases, and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients

    Biomarkers

    (2011)
  • J. Qian et al.

    Characteristics of hepatic IGF-II expression and monitored levels of circulating IGF-II mRNA in metastasis of hepatocellular carcinoma

    Am. J. Clin. Pathol.

    (2010)
  • R.N. Rehem et al.

    Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma

    Hepatogastroenterology

    (2011)
  • J.F. Tsai et al.

    Serum insulin-like growth factor-II and alpha-fetoprotein as tumor markers of hepatocellular carcinoma

    Tumour Biol.

    (2003)
  • J.W. Chen et al.

    A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum

    Am. J. Physiol. Endocrinol. Metab.

    (2003)
  • Cited by (20)

    • Integrated analysis of transcriptomics and metabolomics in human hepatocellular carcinoma HepG2215 cells after YAP1 knockdown

      2023, Acta Histochemica
      Citation Excerpt :

      KNG1 has been proven to be a biomarker for the occurrence of HCC(Jiang et al., 2019a, 2019b), and plays a role in promoting various cancers (Zhang et al., 2020). A decrease in serum IGF1 concentration might be a potential risk factor for HCC progression (Espelund et al., 2015; Yao et al., 2017). The correlation between tissue expression of IGF1 system components and clinicopathological data in patients with HCC confirmed that the decreased expression of IGF1 could also be used as a prognostic marker for HCC (Adamek and Kasprzak, 2018; Kaseb et al., 2011).

    • Insulin-like growth factor (IGF) axis in cancerogenesis

      2017, Mutation Research - Reviews in Mutation Research
    • The insulin-like growth factor-I receptor stimulating activity (IRSA) in health and disease

      2019, Growth Hormone and IGF Research
      Citation Excerpt :

      However, circulating concentrations of IRSA (measured by the IGF-IR KIRA assay), immunoreactive total IGF-I, total IGF-II and IGF-binding proteins did not change, suggesting that other mechanisms than activity of the IGF system are involved in the anabolic effects of TIPS [39]. Circulating IRSA (measured by the IGF-IR KIRA assay) in patients with hepatocellular carcinoma was twice as high as found in patients with liver cirrhosis [23]. However, IRSA concentrations in both groups were markedly below the concentrations observed for healthy controls [23].

    View all citing articles on Scopus
    View full text